Showing results (51-60 of 64) with videos related to
Sort By:
Pageof 7
The Journal of Clinical Investigation|December 18, 2019
Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor modelsLucia Nappi, Adeleke H Aguda, Nader Al Nakouzi, et al.Iscience|August 22, 2020
Interleukin-10 and Small Molecule SHIP1 Allosteric Regulators Trigger Anti-inflammatory Effects through SHIP1/STAT3 ComplexesThomas C Chamberlain, Sylvia T Cheung, Jeff S J Yoon, et al.Bioorganic & Medicinal Chemistry Letters|September 6, 2016
Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacySze-Wan Li, Yong Liu, Peter B Sampson, et al.Journal of Medicinal Chemistry|October 18, 2021
Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate CancerEric Leblanc, Fuqiang Ban, Ayse Derya Cavga, et al.Journal of Chemical Information and Modeling|May 26, 2025
Active Learning-Guided Hit Optimization for the Leucine-Rich Repeat Kinase 2 WDR Domain Based on In Silico Ligand-Binding AffinitiesFilipp Gusev, Evgeny Gutkin, Francesco Gentile, et al.Cancer Letters|February 17, 2019
Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cellsYongmei Feng, E Hampton Sessions, Fan Zhang, et al.Journal of Medicinal Chemistry|July 9, 2013
The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agentsRadoslaw Laufer, Bryan Forrest, Sze-Wan Li, et al.Journal of Medicinal Chemistry|February 28, 2015
The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agentPeter B Sampson, Yong Liu, Bryan Forrest, et al.Journal of Medicinal Chemistry|May 29, 2014
The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agentsPeter B Sampson, Yong Liu, Narendra Kumar Patel, et al.Bioorganic & Medicinal Chemistry|July 22, 2014
Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamidesRadoslaw Laufer, Grace Ng, Yong Liu, et al.Pageof 7